Your browser is no longer supported. Please, upgrade your browser.
INCY Incyte Corporation daily Stock Chart
INCY [NASD]
Incyte Corporation
IndexS&P 500 P/E49.09 EPS (ttm)1.86 Insider Own0.50% Shs Outstand218.55M Perf Week-3.14%
Market Cap20.00B Forward P/E29.71 EPS next Y3.08 Insider Trans-20.69% Shs Float214.05M Perf Month4.67%
Income405.00M PEG0.99 EPS next Q0.58 Inst Own96.60% Short Float2.07% Perf Quarter16.81%
Sales2.11B P/S9.49 EPS this Y133.20% Inst Trans-0.38% Short Ratio3.94 Perf Half Y11.82%
Book/sh11.26 P/B8.13 EPS next Y10.43% ROA14.00% Target Price94.69 Perf Year35.99%
Cash/sh9.09 P/C10.07 EPS next 5Y49.43% ROE18.70% 52W Range57.00 - 96.79 Perf YTD43.91%
Dividend- P/FCF33.96 EPS past 5Y23.80% ROI6.30% 52W High-5.46% Beta0.98
Dividend %- Quick Ratio5.00 Sales past 5Y39.60% Gross Margin95.90% 52W Low60.54% ATR2.14
Employees1367 Current Ratio5.00 Sales Q/Q22.70% Oper. Margin18.50% RSI (14)54.54 Volatility2.49% 2.23%
OptionableYes Debt/Eq0.02 EPS Q/Q335.90% Profit Margin19.20% Rel Volume1.63 Prev Close92.85
ShortableYes LT Debt/Eq0.02 EarningsJan 28 BMO Payout0.00% Avg Volume1.12M Price91.51
Recom2.20 SMA20-0.55% SMA507.96% SMA20011.56% Volume1,835,860 Change-1.44%
Oct-03-19Initiated Mizuho Buy $95
Sep-12-19Initiated BMO Capital Markets Market Perform
Sep-05-19Upgrade Oppenheimer Perform → Outperform $100
Sep-05-19Upgrade JMP Securities Mkt Perform → Mkt Outperform $107
Sep-05-19Resumed Morgan Stanley Equal-Weight $82 → $87
May-21-19Initiated Credit Suisse Neutral $75
May-03-19Downgrade Barclays Overweight → Equal Weight $90 → $82
Apr-11-19Initiated Stifel Hold $82
Apr-03-19Downgrade RBC Capital Mkts Outperform → Sector Perform $89
Jan-24-19Upgrade William Blair Mkt Perform → Outperform
Jan-24-19Upgrade Gabelli & Co Hold → Buy $105
Jan-16-19Downgrade UBS Buy → Neutral
Jan-03-19Upgrade Guggenheim Neutral → Buy
Oct-22-18Upgrade Raymond James Outperform → Strong Buy
Oct-01-18Initiated Cantor Fitzgerald Neutral $73
Sep-25-18Initiated Leerink Partners Mkt Perform
Aug-15-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Aug-01-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Jul-13-18Downgrade Morgan Stanley Overweight → Equal-Weight
Jun-26-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-10-19 04:36PM  Stock Market Claws Back From Early 105-Point Dow Loss, But Still Ends In Red; Apple, Nike Continue Bullish Moves Investor's Business Daily
01:23PM  See 33 Top Stocks Up 32.4% To 145% Year To Date Investor's Business Daily
05:13AM  Moving Average Crossover Alert: Incyte Zacks
Dec-05-19 08:00AM  Incyte to Present at Upcoming Investor Conference Business Wire
Dec-04-19 10:02AM  Biotech Stock Roundup: Pipeline Updates From BIIB, AXSM, CARA, Collaborations & More Zacks
Dec-03-19 10:04AM  Did Hedge Funds Drop The Ball On Incyte Corporation (INCY) ? Insider Monkey
09:00AM  Why You Should Keep An Eye On These 5 Leading Health Care Stocks Investor's Business Daily
Dec-02-19 05:07PM  Is IBD 50 Drugmaker Incyte Stock On The Cusp Of Innovation-Fueled Growth Spurt? Investor's Business Daily
11:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
Nov-29-19 01:23PM  Dow Jones Snaps 4-Day Run-Up; Will These 6 Growth Stocks Jam In December? Investor's Business Daily
Nov-28-19 09:31AM  Why Is Incyte (INCY) Up 12.5% Since Last Earnings Report? Zacks
08:10AM  Incyte's NDA for Pemigatinib Gets FDA's Priority Review Tag Zacks
07:30AM  The 3 Best-Performing Health Care Stocks of 2019 So Far Barrons.com
Nov-27-19 10:12AM  Merck's Keytruda Gets Nod in China for Difficult Lung Cancer Zacks
07:30AM  Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma TEST Business Wire Releases
07:30AM  Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma Business Wire
Nov-25-19 05:18PM  See 12 Stocks Expecting 53% To 208% Earnings Growth This Year Investor's Business Daily +5.94%
03:29PM  This Index Blasts The Dow Jones Gain; Incyte Leads Upside As 4 Growth Stocks Add To Breakouts Investor's Business Daily
12:49PM  The Dow Is Rising Because China Might Finally Target the Theft of Intellectual Property Barrons.com
09:23AM  INCY Ignites Investor's Business Daily Video
08:00AM  Data from Incytes Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting Business Wire
Nov-21-19 06:45PM  Why Dow Jones Stocks Boeing And Caterpillar Are On This Trading Pro's Radar Investor's Business Daily
11:00AM  Top Health Care Stocks for December 2019 Investopedia
10:00AM  Merck's Keytruda Wins EU Nod for First-Line Head/Neck Cancer Zacks
Nov-20-19 04:34PM  IBD Stock Of The Day Flirts With Buy Point As Street Looks Ahead To 2020 Investor's Business Daily
10:00AM  Incyte (INCY) Is Up 1.88% in One Week: What You Should Know Zacks
09:50AM  The Zacks Analyst Blog Highlights: Alexion Pharmaceuticals, Vertex Pharmaceuticals, Incyte and Regeneron Pharmaceuticals Zacks
08:58AM  INCY Breaks Out Investor's Business Daily Video
Nov-19-19 10:14AM  4 Big Biotech Stocks Worth Considering Post Q3 Earnings Zacks
07:47AM  Update: Incyte (NASDAQ:INCY) Stock Gained 36% In The Last Year Simply Wall St.
Nov-14-19 08:00AM  Incyte to Present at Upcoming Investor Conference Business Wire
Nov-12-19 08:18AM  The Zacks Analyst Blog Highlights: Coherus, Incyte, ACADIA and Celgene Zacks
Nov-11-19 09:28AM  4 Biotech Stocks That Could Keep Beating Wall Street Zacks
08:56AM  U.S. company directors compensated more than ever, but now risk backlash Reuters
Nov-06-19 11:35AM  Constellation shares soar 95% after promising data from rare disease trial MarketWatch
Nov-05-19 10:20AM  Will Incyte (INCY) Gain on Rising Earnings Estimates? Zacks
10:17AM  The Zacks Analyst Blog Highlights: Sony, Allstate and Incyte Zacks
10:00AM  Looking For Growth? Take A Look At These Biotechnology Stocks Investor's Business Daily
Oct-30-19 02:40PM  Edited Transcript of INCY earnings conference call or presentation 29-Oct-19 12:00pm GMT Thomson Reuters StreetEvents
02:35PM  IBD 50 Stocks To Watch: Why Top Biotech Incyte Is Near Buy Point After Blowout Earnings Investor's Business Daily
Oct-29-19 04:09PM  Will This Biotech's Solid Quarter Be Enough To Help It Break Out? Investor's Business Daily
01:26PM  The Dow Is Up a Few Points Because Hope on Trade Isnt the Same as Rocket Fuel Barrons.com
11:10AM  Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View Zacks
08:15AM  Incyte (INCY) Q3 Earnings and Revenues Top Estimates Zacks
07:00AM  Incyte Reports 2019 Third Quarter Financial Results and Provides Updates on Key Clinical Programs Business Wire
Oct-28-19 06:32PM  Boeing CEO heads to Capitol Hill What to know in markets Tuesday Yahoo Finance
05:10PM  11 Stocks With The Highest Gross Margins Benzinga
11:59AM  Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More Zacks
11:33AM  Sanofi (SNY) to Report Q3 Earnings: What's in the Cards? Zacks
09:31AM  Imbruvica to Offset Humira Woes in AbbVie (ABBV) Q3 Earnings? Zacks
Oct-25-19 12:12PM  Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings? Zacks
12:06PM  Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings? Zacks
11:10AM  What's in the Cards for AbbVie (ABBV) This Earnings Season? Zacks
10:51AM  Lannett (LCI) to Report Q1 Earnings: What's in the Cards? Zacks
Oct-24-19 12:50PM  BioMarin's (BMRN) Earnings & Revenues Beat Estimates in Q3 Zacks
11:24AM  Acorda (ACOR) to Post Q3 Earnings: What's in the Cards? Zacks
11:18AM  Will Top-Line Decline Hurt Corning's (GLW) Q3 Earnings? Zacks
10:50AM  5 Drug/Biotech Stocks Likely to Surpass on Earnings in Q3 Zacks
10:39AM  Baxter (BAX) Misses Q3 Revenue Estimates, Issues Guidance Zacks
09:54AM  AstraZeneca (AZN) Q3 Earnings Top, Upgrades '19 Sales View Zacks
08:40AM  Factors Setting the Tone for Celgene (CELG) Q3 Earnings Zacks
08:14AM  Incyte Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-23-19 03:26PM  16 Stocks With The Highest Long-Term Sales Growth Rate Benzinga
11:26AM  Alexion (ALXN) Beats on Q3 Earnings, Lifts 2019 Guidance Zacks
10:53AM  Is a Beat in Store for Glaxo (GSK) This Earnings Season? Zacks
10:07AM  Will Strong Jakafi Sales Drive Incyte's (INCY) Q3 Earnings? Zacks
09:51AM  T-Mobile (TMUS) to Report Q3 Earnings: Is a Beat in Store? Zacks
08:54AM  What Awaits SBA Communications (SBAC) This Earnings Season? Zacks
Oct-22-19 10:00AM  What's in the Cards for Sarepta (SRPT) This Earnings Season? Zacks
08:00AM  Incyte to Present at Upcoming Investor Conference Business Wire
Oct-21-19 12:14PM  What's in the Cards for AstraZeneca (AZN) in Q3 Earnings? Zacks
10:25AM  Nokia (NOK) to Report Q3 Earnings: What's in the Offing? Zacks
Oct-18-19 10:10AM  Why the Earnings Surprise Streak Could Continue for Incyte (INCY) Zacks
Oct-17-19 12:12PM  Novartis' Jakavi Meets Primary Goal in Phase III for GVHD Zacks
Oct-16-19 12:16PM  Editas Inks Deal for Gene Editing Neurological Disease Drugs Zacks
12:15PM  Novavax Begins Phase III Study on Influenza Vaccine Candidate Zacks
07:59AM  Incyte reports positive results in late-stage trial of treatment for GVHD MarketWatch
07:00AM  Incyte Announces that the REACH2 Pivotal Trial of Ruxolitinib (Jakafi®) Meets Primary Endpoint in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease Business Wire
Oct-15-19 03:53PM  Were Hedge Funds Right About Dumping Incyte Corporation (INCY)? Insider Monkey
10:57AM  Ultragenyx's (RARE) NDA for LC-FAOD Drug Accepted by FDA Zacks
Oct-14-19 11:46AM  Blueprint Medicines' Avapritinib Grows to Curb Revenue Reliance Zacks
09:44AM  Is Incyte Corporation's (NASDAQ:INCY) CEO Pay Justified? Simply Wall St.
Oct-12-19 02:32AM  Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo Business Wire
Oct-11-19 12:40PM  Seattle Genetics Begins Phase III Study on Tucatinib Combo Zacks
Oct-10-19 11:17AM  bluebird Inks Genome Editing Research Deal With Novo Nordisk Zacks
08:00AM  Incyte to Report Third Quarter Financial Results Business Wire
Oct-08-19 06:45AM  Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress PR Newswire
Oct-04-19 11:33AM  Puma Biotech Gets FDA Nod of Labeling Supplement for Nerlynx Zacks
09:30AM  3 Drug Stocks Poised for Gains After Cancer Conference Investopedia
05:28AM  Incyte Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-03-19 04:47PM  Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down Zacks
11:22AM  Merck's Pediatric Filings for Dificid Get FDA's Priority Review Zacks
09:30AM  Is Incyte (INCY) Stock Outpacing Its Medical Peers This Year? Zacks
07:00AM  Amgen, Merck and Others Highlighted Cancer-Drug Developments in Barcelona Barrons.com
Sep-30-19 06:00AM  The 3 Best Health-Care Stocks This Month. And the Worst Barrons.com
Sep-29-19 03:01PM  The Week Ahead In Biotech (Sept. 29-Oct. 5): Conference Presentations, IPOs Hit Top Gear Benzinga
Sep-27-19 10:47AM  Incyte (INCY) Stock Up 16% YTD on Strong Jakafi Performance Zacks
09:39AM  CORRECTING and REPLACING Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma Business Wire
Sep-26-19 10:46AM  A Big Cancer Conference Starts Tomorrow. Heres What It Means for Merck, Bristol-Myers and Other Drug Stocks. Barrons.com
09:02AM  Incyte Treats First Patient in Phase III Vitiligo Study Zacks
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naive acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flannelly Barry PEVP & General Manager USDec 02Option Exercise73.216,582481,86823,561Dec 03 04:20 PM
Iyengar Vijay KEVP GPS, BD, & LicensingDec 02Option Exercise72.867,366536,68724,975Dec 03 04:25 PM
Wenqing YaoEVP, Head of Discovery ChemDec 02Option Exercise18.3216,835308,417112,143Dec 03 04:32 PM
Iyengar Vijay KEVP GPS, BD, & LicensingDec 02Sale95.007,366699,77017,609Dec 03 04:25 PM
Wenqing YaoEVP, Head of Discovery ChemDec 02Sale95.0016,8351,599,32595,308Dec 03 04:32 PM
Flannelly Barry PEVP & General Manager USDec 02Sale95.006,582625,29016,979Dec 03 04:20 PM
Flannelly Barry PEVP & General Manager USNov 29Option Exercise73.2160043,92617,579Dec 03 04:20 PM
Iyengar Vijay KEVP GPS, BD, & LicensingNov 29Option Exercise72.8650036,43018,109Dec 03 04:25 PM
Wenqing YaoEVP, Head of Discovery ChemNov 29Option Exercise18.323,16557,98398,473Dec 03 04:32 PM
Wenqing YaoEVP, Head of Discovery ChemNov 29Sale95.003,165300,67595,308Dec 03 04:32 PM
Iyengar Vijay KEVP GPS, BD, & LicensingNov 29Sale95.0050047,50017,609Dec 03 04:25 PM
Flannelly Barry PEVP & General Manager USNov 29Sale95.0060057,00016,979Dec 03 04:20 PM
Trower PaulPrincipal Accounting OfficerNov 25Option Exercise18.3215,000274,80032,306Nov 26 04:06 PM
Wenqing YaoEVP, Head of Discovery ChemNov 25Option Exercise18.3215,000274,800110,308Nov 26 04:11 PM
Flannelly Barry PEVP & General Manager USNov 25Option Exercise48.442,142103,75818,699Nov 26 04:31 PM
Flannelly Barry PEVP & General Manager USNov 25Sale90.002,142192,78016,979Nov 26 04:31 PM
Wenqing YaoEVP, Head of Discovery ChemNov 25Sale90.0015,0001,350,00095,308Nov 26 04:11 PM
Trower PaulPrincipal Accounting OfficerNov 25Sale90.0015,0001,350,00017,306Nov 26 04:06 PM
SWAIN PAULA JEVP, Human ResourcesNov 15Option Exercise64.552,500161,37544,112Nov 19 05:45 PM
SWAIN PAULA JEVP, Human ResourcesNov 15Sale86.462,500216,15041,612Nov 19 05:45 PM
Pasquale Maria EEVP & General CounselNov 13Option Exercise65.36764,96718,756Nov 14 05:32 PM
DIXON WENDY LDirectorNov 08Option Exercise12.4641,218513,57635,224Nov 08 05:25 PM
DIXON WENDY LDirectorNov 08Sale83.8741,2183,456,95412,340Nov 08 05:25 PM
DIXON WENDY LDirectorNov 07Option Exercise12.461,54019,18813,880Nov 08 05:25 PM
DIXON WENDY LDirectorNov 07Sale83.601,540128,74412,340Nov 08 05:25 PM
DIXON WENDY LDirectorNov 06Option Exercise12.4610,576131,77722,916Nov 08 05:25 PM
DIXON WENDY LDirectorNov 06Sale84.1610,576890,07612,340Nov 08 05:25 PM
Trower PaulPrincipal Accounting OfficerNov 01Option Exercise18.328,500155,72025,806Nov 05 04:33 PM
Wenqing YaoEVP, Head of Discovery ChemNov 01Option Exercise18.327,960145,827103,268Nov 05 05:23 PM
Wenqing YaoEVP, Head of Discovery ChemNov 01Sale85.007,960676,60095,308Nov 05 05:23 PM
Trower PaulPrincipal Accounting OfficerNov 01Sale85.008,500722,50017,306Nov 05 04:33 PM
Trower PaulPrincipal Accounting OfficerOct 29Option Exercise18.3216,500302,28025,705Oct 31 04:07 PM
Wenqing YaoEVP, Head of Discovery ChemOct 29Option Exercise18.322,04037,37347,348Oct 31 04:10 PM
Wenqing YaoEVP, Head of Discovery ChemOct 29Sale85.002,040173,40045,308Oct 31 04:10 PM
Trower PaulPrincipal Accounting OfficerOct 29Sale80.4516,5001,327,50017,306Oct 31 04:07 PM
Iyengar Vijay KEVP GPS, BD, & LicensingOct 29Sale85.0093079,05017,609Oct 31 04:00 PM
SWAIN PAULA JEVP, Human ResourcesOct 22Option Exercise64.552,500161,37544,112Oct 24 06:52 PM
SWAIN PAULA JEVP, Human ResourcesOct 22Sale80.002,500200,00041,612Oct 24 06:52 PM
Pasquale Maria EEVP & General CounselOct 10Option Exercise65.36775,03318,680Oct 11 04:40 PM
SWAIN PAULA JEVP, Human ResourcesSep 18Option Exercise64.552,500161,37544,112Sep 19 04:34 PM
SWAIN PAULA JEVP, Human ResourcesSep 18Sale80.002,500200,00041,612Sep 19 04:34 PM
Flannelly Barry PEVP & General Manager USSep 17Sale77.712,491193,57616,757Sep 19 04:30 PM
Pasquale Maria EEVP & General CounselSep 09Option Exercise65.36764,96718,603Sep 11 04:29 PM
SWAIN PAULA JEVP, Human ResourcesAug 15Option Exercise64.552,500161,37544,112Aug 19 04:21 PM
SWAIN PAULA JEVP, Human ResourcesAug 15Sale80.962,500202,40041,612Aug 19 04:21 PM
Pasquale Maria EEVP & General CounselAug 09Option Exercise65.361,22379,93518,527Aug 13 04:35 PM
FRIEDMAN PAUL ADirectorAug 06Option Exercise18.3277,9341,427,751333,465Aug 06 06:45 PM
FRIEDMAN PAUL ADirectorAug 06Sale82.2077,9346,406,175255,531Aug 06 06:45 PM
FRIEDMAN PAUL ADirectorAug 02Option Exercise18.3222,066404,249277,597Aug 06 06:45 PM
FRIEDMAN PAUL ADirectorAug 02Sale84.4122,0661,862,591255,531Aug 06 06:45 PM
BIENAIME JEAN JACQUESDirectorAug 02Sale84.7337731,9437,055Aug 05 04:36 PM
BIENAIME JEAN JACQUESDirectorAug 01Sale85.161,347114,7117,432Aug 05 04:36 PM
Flannelly Barry PEVP & General Manager USJul 17Sale79.9195976,63419,248Jul 18 06:13 PM
SWAIN PAULA JEVP, Human ResourcesJul 15Option Exercise64.552,500161,37544,751Jul 16 04:48 PM
SWAIN PAULA JEVP, Human ResourcesJul 15Sale80.002,500200,00042,251Jul 16 04:48 PM
Stein Steven HEVP & Chief Medical OfficerJun 24Sale87.968,357735,08210,805Jun 25 05:46 PM
SWAIN PAULA JEVP, Human ResourcesJun 17Option Exercise64.552,500161,37539,013Jun 18 05:26 PM
SWAIN PAULA JEVP, Human ResourcesJun 17Sale80.002,500200,00036,513Jun 18 05:26 PM
SWAIN PAULA JEVP, Human ResourcesApr 01Option Exercise18.3210,000183,20044,731Apr 02 04:51 PM
SWAIN PAULA JEVP, Human ResourcesApr 01Sale87.0110,000870,10036,513Apr 02 04:51 PM
SWAIN PAULA JEVP, Human ResourcesMar 01Option Exercise18.3210,000183,20046,513Mar 05 04:45 PM
SWAIN PAULA JEVP, Human ResourcesMar 01Sale86.6810,000866,80036,513Mar 05 04:45 PM
BAKER BROS. ADVISORS LPDirectorFeb 26Option Exercise2.8040,000112,00029,288,793Feb 27 05:19 PM
SWAIN PAULA JEVP, Human ResourcesFeb 01Option Exercise18.3210,000183,20041,124Feb 05 04:36 PM
SWAIN PAULA JEVP, Human ResourcesFeb 01Sale81.1910,000811,90031,124Feb 05 04:36 PM
Flannelly Barry PEVP & General Manager USJan 28Sale80.001,00080,0008,944Jan 30 04:22 PM
Wenqing YaoEVP, Head of Discovery ChemJan 17Option Exercise17.7915,354273,14849,763Jan 22 06:04 PM
Wenqing YaoEVP, Head of Discovery ChemJan 17Sale77.6115,3541,191,62434,409Jan 22 06:04 PM
Trower PaulPrincipal Accounting OfficerJan 15Option Exercise17.795,813103,41319,713Jan 17 04:15 PM
Trower PaulPrincipal Accounting OfficerJan 15Sale75.005,813435,97513,900Jan 17 04:15 PM
Flannelly Barry PEVP & General Manager USJan 08Sale75.561,714129,5109,944Jan 10 04:11 PM
Trower PaulPrincipal Accounting OfficerJan 07Option Exercise17.799,187163,43723,359Jan 08 04:42 PM
Wenqing YaoEVP, Head of Discovery ChemJan 07Option Exercise17.7910,000177,90045,217Jan 08 04:46 PM
Wenqing YaoEVP, Head of Discovery ChemJan 07Sale75.0010,000750,00035,217Jan 08 04:46 PM
Trower PaulPrincipal Accounting OfficerJan 07Sale75.009,187689,02514,172Jan 08 04:42 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Option Exercise18.3230,000549,60062,324Jan 08 04:37 PM
SWAIN PAULA JEVP, Human ResourcesJan 04Sale70.0030,0002,100,00032,324Jan 08 04:37 PM